Literature DB >> 6424820

Flexible induction dose regimen for warfarin and prediction of maintenance dose.

A Fennerty, J Dolben, P Thomas, G Backhouse, D P Bentley, I A Campbell, P A Routledge.   

Abstract

Fifty patients with venous thromboembolic disease being treated by heparin infusion received a three day warfarin induction regimen tailored according to the prothrombin time (British comparative ratio) measured on days 2 and 3. A prediction of the final maintenance dose of warfarin was made on the basis of a prothrombin time measured on day 4. All patients were safely anticoagulated by day 6, and the prediction was accurate to within 1 mg in 46 patients. Predicted and actual maintenance doses were closely related (r = 0.867; n = 50; p less than 0.001). This scheme should prove helpful in the control of anticoagulation, particularly in patients likely to be sensitive to warfarin, and should shorten hospital stay.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424820      PMCID: PMC1441080          DOI: 10.1136/bmj.288.6426.1268

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  9 in total

1.  Predicting warfarin requirements.

Authors:  P A Routledge; D M Davies; M D Rawlins
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

2.  Predicting warfarin requirements.

Authors:  P J Green
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

3.  Predicting warfarin requirements.

Authors:  G W Morrison
Journal:  Lancet       Date:  1979-01-20       Impact factor: 79.321

4.  Monitoring effects of oral anticoagulants during treatment with heparin.

Authors:  P Thomas; A Fennerty; G Backhouse; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-21

5.  Predicting patients' warfarin requirements.

Authors:  P A Routledge; D M Davies; S M Bell; J S Cavanagh; M D Rawlins
Journal:  Lancet       Date:  1977-10-22       Impact factor: 79.321

6.  Factors affecting warfarin requirements. A prospective population study.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

7.  Predicting the dose of warfarin for therapeutic anticoagulation.

Authors:  N K Sharma; P A Routledge; M D Rawlins; D M Davies
Journal:  Thromb Haemost       Date:  1982-06-28       Impact factor: 5.249

8.  A simple technic for predicting daily maintenance dose of warfarin.

Authors:  D B Williams; R C Karl
Journal:  Am J Surg       Date:  1979-04       Impact factor: 2.565

9.  Predicting warfarin maintenance dosage based on initial response.

Authors:  D R Miller; M A Brown
Journal:  Am J Hosp Pharm       Date:  1979-10
  9 in total
  46 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

4.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 5.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Best practice in primary care pathology: review 8.

Authors:  W S A Smellie; K K Hampton; R Bowley; R Bowlees; S C Martin; N Shaw; J Hoffman; J P Ng; S M Mackenzie; C van Heyningen
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

7.  Clarification of terminology in medication errors: definitions and classification.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.

Authors:  Jacob P Deerhake; Julie C Merz; Jeanna V Cooper; Kim A Eagle; William P Fay
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

9.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

10.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.